

Jun Toyohara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9441672/publications.pdf>

Version: 2024-02-01

134
papers

2,228
citations

236925

25
h-index

302126

39
g-index

137
all docs

137
docs citations

137
times ranked

2528
citing authors

#	ARTICLE	IF	CITATIONS
1	Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nuclear Medicine and Biology, 2002, 29, 281-287.	0.6	100
2	Basic characterization of ⁶⁴ Cu-ATSM as a radiotherapy agent. Nuclear Medicine and Biology, 2005, 32, 21-28.	0.6	93
3	$\alpha 7$ Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease-!2009-10-15~!2009-10-30~!2010-05-27~!. Open Medicinal Chemistry Journal, 2010, 4, 37-56.	2.4	85
4	Preclinical and the first clinical studies on [¹¹ C]CHIBA-1001 for mapping $\alpha 7$ nicotinic receptors by positron emission tomography. Annals of Nuclear Medicine, 2009, 23, 301-309.	2.2	75
5	Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Physica Medica, 2017, 42, 203-210.	0.7	73
6	High occupancy of $\beta 1$ receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [¹¹ C]SA4503. International Journal of Neuropsychopharmacology, 2009, 12, 1127.	2.1	63
7	Changes in Cerebral Blood Flow during Steady-State Cycling Exercise: A Study Using Oxygen-15-Labeled Water with PET. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 389-396.	4.3	61
8	$\alpha 7$ Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. Open Medicinal Chemistry Journal, 2010, 4, 37-56.	2.4	56
9	[¹¹ C]Gefitinib ([¹¹ C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma. Molecular Imaging and Biology, 2010, 12, 181-191.	2.6	54
10	Feasibility studies of ⁴ α -[methyl- ¹¹ C]thiothymidine as a tumor proliferation imaging agent in mice. Nuclear Medicine and Biology, 2008, 35, 67-74.	0.6	52
11	Imaging of Sigma1 Receptors in the Human Brain Using PET and [¹¹ C]SA4503. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 190-196.	1.1	49
12	⁴ α -[Methyl- ¹¹ C]-Thiothymidine PET/CT for Proliferation Imaging in Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 199-206.	5.0	43
13	Comparison of ¹¹ C- ⁴ α -thiothymidine, ¹¹ C-methionine, and ¹⁸ F-FDG PET/CT for the detection of active lesions of multiple myeloma. Annals of Nuclear Medicine, 2015, 29, 224-232.	2.2	42
14	Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Annals of Nuclear Medicine, 2013, 27, 285-296.	2.2	39
15	Whole-Body Distribution and Brain Tumor Imaging with ¹¹ C-4DST: A Pilot Study. Journal of Nuclear Medicine, 2011, 52, 1322-1328.	5.0	38
16	Trends in nucleoside tracers for PET imaging of cell proliferation. Nuclear Medicine and Biology, 2003, 30, 681-685.	0.6	36
17	Regional Cerebral Glucose Metabolism and Gait Speed in Healthy Community-Dwelling Older Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1519-1527.	3.6	35
18	Initial Human PET Studies of Metabotropic Glutamate Receptor Type 1 Ligand ¹¹ C-ITMM. Journal of Nuclear Medicine, 2013, 54, 1302-1307.	5.0	34

#	ARTICLE	IF	CITATIONS
19	Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1717-22.	5.0	33
20	Recent Development of Radioligands for Imaging $\alpha 7$ Nicotinic Acetylcholine Receptors in the Brain. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1544-1557.	2.1	32
21	In Vivo Evaluation of $\alpha 7$ Nicotinic Acetylcholine Receptor Agonists [11C]A-582941 and [11C]A-844606 in Mice and Conscious Monkeys. <i>PLoS ONE</i> , 2010, 5, e8961.	2.5	31
22	Biodistribution and radiation dosimetry of the $\alpha 7$ nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in humans. <i>Nuclear Medicine and Biology</i> , 2011, 38, 443-448.	0.6	31
23	Brain histamine H ₁ receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 199-206.	2.4	31
24	Occupancy of adenosine A _{2A} receptors by istradefylline in patients with Parkinson's disease using 11C-preladenant PET. <i>Neuropharmacology</i> , 2018, 143, 106-112.	4.1	29
25	Characterization of [3H]CHIBA-1001 binding to $\alpha 7$ nicotinic acetylcholine receptors in the brain from rat, monkey, and human. <i>Brain Research</i> , 2010, 1348, 200-208.	2.2	27
26	Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2014, 40, 2701-2706.	2.6	26
27	Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier. <i>Neuropharmacology</i> , 2017, 116, 247-259.	4.1	26
28	Occupancy of $\alpha 7$ Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [11C]CHIBA-1001 in Healthy Human Subjects. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 111-116.	2.0	25
29	Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases. <i>Molecules</i> , 2018, 23, 300.	3.8	24
30	Rationale of 5-(125I)iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1218-26.	5.0	24
31	Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1790-1799.	2.1	23
32	Initial Evaluation of an Adenosine A _{2A} Receptor Ligand, ¹¹ C-Preladenant, in Healthy Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1464-1470.	5.0	23
33	Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction. <i>Clinical Nuclear Medicine</i> , 2017, 42, e523-e524.	1.3	23
34	Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. <i>Nuclear Medicine and Biology</i> , 2003, 30, 687-696.	0.6	22
35	Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. <i>Nuclear Medicine and Biology</i> , 2009, 36, 379-388.	0.6	21
36	Basal μ -opioid receptor availability in the amygdala predicts the inhibition of pain-related brain activity during heterotopic noxious counter-stimulation. <i>Neuroscience Research</i> , 2014, 81-82, 78-84.	1.9	21

#	ARTICLE	IF	CITATIONS
37	Alkyl-fluorinated thymidine derivatives for imaging cell proliferation. <i>Nuclear Medicine and Biology</i> , 2006, 33, 765-772.	0.6	20
38	Preclinical and the first clinical studies on [11C]ITMM for mapping metabotropic glutamate receptor subtype 1 by positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2013, 40, 214-220.	0.6	20
39	Evaluation of 4â€²-[Methyl-11C]Thiothymidine in a Rodent Tumor and Inflammation Model. <i>Journal of Nuclear Medicine</i> , 2012, 53, 488-494.	5.0	19
40	18F-THK5351 PET Can Identify Astrogliosis in Multiple Sclerosis Plaques. <i>Clinical Nuclear Medicine</i> , 2020, 45, e98-e100.	1.3	19
41	Differential effects of age on human striatal adenosine A₁ and A_{2A} receptors. <i>Synapse</i> , 2012, 66, 832-839.	1.2	18
42	Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [11C]CB184 and [11C]CB190, as a PET tracer for 18ÅkDa translocator protein: direct comparison with [11C](R)-PK11195. <i>Annals of Nuclear Medicine</i> , 2015, 29, 325-335.	2.2	17
43	Comparison of 4â€²-[methyl-11C]thiothymidine (11C-4DST) and 3â€²-deoxy-3â€²-[18F]fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging. <i>EJNMMI Research</i> , 2015, 5, 7.	2.5	16
44	Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. <i>Annals of Nuclear Medicine</i> , 2019, 33, 375-382.	2.2	16
45	A pilot study of 4â€²-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer. <i>EJNMMI Research</i> , 2014, 4, 10.	2.5	15
46	Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 507-509.	1.3	15
47	Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders. <i>Clinical Nuclear Medicine</i> , 2021, 46, e31-e33.	1.3	15
48	Alkyl-fluorinated thymidine derivatives for imaging cell proliferation. <i>Nuclear Medicine and Biology</i> , 2006, 33, 751-764.	0.6	14
49	Volumetric comparison of positron emission tomography/computed tomography using 4â€²-[methyl-11C]-thiothymidine with 2-deoxy-2-18F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma. <i>Nuclear Medicine Communications</i> , 2015, 36, 219-225.	1.1	14
50	Evaluation of [11C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1106-1118.	6.4	14
51	Correlation of 4â€²-[methyl-11C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with 11C-methionine uptake. <i>Annals of Nuclear Medicine</i> , 2016, 30, 89-96.	2.2	14
52	Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Bloodâ€”Brain Barrier in Non-Human Primates with PET. <i>Molecular Pharmaceutics</i> , 2020, 17, 3477-3486.	4.6	14
53	11C-Labeled Analogs of Indomethacin Esters and Amides for Brain Cyclooxygenase-2 Imaging: Radiosynthesis, in Vitro Evaluation and in Vivo Characteristics in Mice. <i>Chemical and Pharmaceutical Bulletin</i> , 2011, 59, 938-946.	1.3	13
54	Pharmacokinetics and metabolism of 5-125I-iodo-4'-thio-2'-deoxyuridine in rodents. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1671-6.	5.0	13

#	ARTICLE	IF	CITATIONS
55	Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center. <i>Geriatrics and Gerontology International</i> , 2010, 10, S180-96.	1.5	12
56	In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. <i>Nuclear Medicine and Biology</i> , 2011, 38, 517-527.	0.6	12
57	Re-evaluation of in vivo selectivity of [¹¹ C]SA4503 to 5-HT ₁ receptors in the brain: Contributions of emopamil binding protein. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1049-1052.	0.6	12
58	Longitudinal observation of [¹¹ C]4DST uptake in turpentine-induced inflammatory tissue. <i>Nuclear Medicine and Biology</i> , 2013, 40, 240-244.	0.6	12
59	In vitro analysis of transport and metabolism of 4- ¹⁴ C-thiothymidine in human tumor cells. <i>Nuclear Medicine and Biology</i> , 2015, 42, 470-474.	0.6	12
60	Comparison of ¹¹ C-4DST and ¹⁸ F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. <i>Abdominal Radiology</i> , 2016, 41, 521-530.	2.1	12
61	Relationship between type 1 metabotropic glutamate receptors and cerebellar ataxia. <i>Journal of Neurology</i> , 2016, 263, 2179-2187.	3.6	12
62	Unchanged type 1 metabotropic glutamate receptor availability in patients with Alzheimer's disease: A study using ¹¹ C-ITMM positron emission tomography. <i>NeuroImage: Clinical</i> , 2019, 22, 101783.	2.7	12
63	Animal tumor models for PET in drug development. <i>Annals of Nuclear Medicine</i> , 2011, 25, 717-731.	2.2	11
64	Comparison of imaging using ¹¹ C-ITMM and ¹⁸ F-FDG for the detection of cerebellar ataxia. <i>Journal of the Neurological Sciences</i> , 2017, 375, 97-102.	0.6	11
65	Pharmacological characterization of [¹²⁵ I]CHIBA-1006 binding, a new radioligand for $\alpha 7$ nicotinic acetylcholine receptors, to rat brain membranes. <i>Brain Research</i> , 2010, 1360, 130-137.	2.2	10
66	Preclinical and first-in-man studies of [¹¹ C]CB184 for imaging the 18-kDa translocator protein by positron emission tomography. <i>Annals of Nuclear Medicine</i> , 2016, 30, 534-543.	2.2	10
67	¹⁸ F-FDG and ¹¹ C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study. <i>EJNMMI Research</i> , 2019, 9, 4.	2.5	10
68	Metabolic Network Topology of Alzheimer's Disease and Dementia with Lewy Bodies Generated Using Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 197-207.	2.6	10
69	Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using ¹⁸ F-THK5351 positron emission tomography. <i>BMC Medical Imaging</i> , 2020, 20, 81.	2.7	10
70	Mechanical Regulation Underlies Effects of Exercise on Serotonin-Induced Signaling in the Prefrontal Cortex Neurons. <i>iScience</i> , 2020, 23, 100874.	4.1	10
71	Adenosine ^{2A} Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 853-857.	3.9	10
72	Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring. <i>Nuclear Medicine and Biology</i> , 2006, 33, 29-35.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Age-Related Decrease in Male Extra-Striatal Adenosine A ₁ Receptors Measured Using ¹¹ C-MPDX PET. <i>Frontiers in Pharmacology</i> , 2017, 8, 903.	3.5	9
74	Response of Cerebral Blood Flow and Blood Pressure to Dynamic Exercise: A Study Using PET. <i>International Journal of Sports Medicine</i> , 2018, 39, 181-188.	1.7	9
75	Increased Binding Potential of Brain Adenosine A ₁ Receptor in Chronic Stages of Patients with Diffuse Axonal Injury Measured with [¹¹ C]-8-dicyclopropylmethyl-1-methyl-3-propylxanthine Positron Emission Tomography Imaging. <i>Journal of Neurotrauma</i> , 2018, 35, 25-31.	3.4	9
76	A pitfall of white matter reference regions used in [¹⁸ F] florbetapir PET: a consideration of kinetics. <i>Annals of Nuclear Medicine</i> , 2019, 33, 848-854.	2.2	9
77	Pharmacological Characterization of [³ H]CHIBA-3007 Binding to Glycine Transporter 1 in the Rat Brain. <i>PLoS ONE</i> , 2011, 6, e21322.	2.5	9
78	PET Imaging of [¹⁸ F]-FDG, [¹¹ C]-methionine, [¹¹ C]-flumazenil, and [¹¹ C]-4DST in Progressive Multifocal Leukoencephalopathy. <i>Internal Medicine</i> , 2017, 56, 1219-1223.	0.7	9
79	Reliable radiosynthesis of 4-[¹⁰ B]borono-2-[¹⁸ F]fluoro-L-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis. <i>Annals of Nuclear Medicine</i> , 2018, 32, 463-473.	2.2	8
80	Efficacy of ⁴ β-[methyl- ¹¹ C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study. <i>EJNMMI Research</i> , 2019, 9, 10.	2.5	8
81	Preclinical Evaluation of an ¹⁸ F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain. <i>ACS Chemical Neuroscience</i> , 2021, 12, 746-755.	3.5	8
82	Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [¹⁸ F]FDG and [¹¹ C]PiB. <i>Medical Physics</i> , 2022, 49, 2995-3005.	3.0	8
83	Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain. <i>Clinical Nuclear Medicine</i> , 2022, 47, e489-e495.	1.3	8
84	Synthesis and evaluation of ⁷ β-(3-[¹⁸ F]fluoropropyl) estradiol. <i>Nuclear Medicine and Biology</i> , 2015, 42, 590-597.	0.6	7
85	Evaluation of peri-implant bone metabolism under immediate loading using high-resolution Na ¹⁸ F-PET. <i>Clinical Oral Investigations</i> , 2017, 21, 2029-2037.	3.0	7
86	Dynamic Exercise Elicits Dissociated Changes Between Tissue Oxygenation and Cerebral Blood Flow in the Prefrontal Cortex: A Study Using NIRS and PET. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 269-274.	1.6	7
87	Evaluation of P-glycoprotein function at the blood-brain barrier using [¹⁸ F]MC225-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4105-4106.	6.4	7
88	Importance of P-gp PET Imaging in Pharmacology. <i>Current Pharmaceutical Design</i> , 2016, 22, 5830-5836.	1.9	7
89	Age and gender effects of ¹¹ C-ITMM binding to metabotropic glutamate receptor type 1 in healthy human participants. <i>Neurobiology of Aging</i> , 2017, 55, 72-77.	3.1	6
90	Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [¹¹ C]CB184, in healthy human volunteers. <i>EJNMMI Research</i> , 2017, 7, 26.	2.5	6

#	ARTICLE	IF	CITATIONS
91	Effects of a novel tungsten-impregnated rubber neck shield on the quality of cerebral images acquired using ¹⁵ O-labeled gas. <i>Radiological Physics and Technology</i> , 2017, 10, 422-430.	1.9	6
92	⁴ Î²-[methyl- ¹¹ C]-thiothymidine as a proliferation imaging tracer for detection of colorectal cancer: comparison with ¹⁸ F-FDG. <i>Annals of Nuclear Medicine</i> , 2019, 33, 822-827.	2.2	6
93	Effects of ¹⁸ F-fluorinated neopentyl glycol side-chain on the biological characteristics of stilbene amyloid-Î² PET ligands. <i>Nuclear Medicine and Biology</i> , 2021, 94-95, 38-45.	0.6	6
94	Head-to-head comparison of (R)-[¹¹ C]verapamil and [¹⁸ F]MC225 in non-human primates, tracers for measuring P-glycoprotein function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4307-4317.	6.4	6
95	<i>Alkyl 3-aminobutanenitrile as a Non-radioactive Side Product in Nucleophilic ¹⁸F-Fluorination</i> . <i>ChemistrySelect</i> , 2021, 6, 2826-2831.	1.5	5
96	Automated synthesis, preclinical toxicity, and radiation dosimetry of [¹⁸ F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier. <i>EJNMMI Research</i> , 2020, 10, 84.	2.5	5
97	Evaluation of DNA synthesis with carbon-11-labeled ⁴ Î²-thiothymidine. <i>World Journal of Radiology</i> , 2016, 8, 799.	1.1	5
98	Application of [¹¹ C]SA4503 to selection of novel Î²1 selective agonists. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1117-1121.	0.6	4
99	Differential human brain activity induced by two perceptually indistinguishable gentle cutaneous stimuli. <i>NeuroReport</i> , 2013, 24, 425-430.	1.2	4
100	Microglial Activation on ¹¹ C-CB184 PET in a Patient With Cerebellar Ataxia Associated With HIV Infection. <i>Clinical Nuclear Medicine</i> , 2018, 43, e82-e84.	1.3	4
101	Searching for diagnostic properties of novel fluorine-18-labeled d-allose. <i>Annals of Nuclear Medicine</i> , 2019, 33, 855-865.	2.2	4
102	Radiosynthesis and preliminary evaluation of an ¹⁸ F-labeled tubastatin A analog for PET imaging of histone deacetylase 6. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 85-95.	1.0	4
103	Automated production of [¹⁸ F]MK-6240 on CFN-MPS200. <i>Applied Radiation and Isotopes</i> , 2021, 168, 109468.	1.5	4
104	Radiosynthesis and <i>in Vivo</i> and <i>ex Vivo</i> Evaluation of Isomeric [¹¹ C]methoxy Analogs of Nimesulide as Brain Cyclooxygenase-2-Targeted Imaging Agents. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 94-103.	1.4	4
105	Comparison of dosimetry between PET/CT and PET alone using ¹¹ C-ITMM. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2016, 39, 177-186.	1.3	3
106	(R)-[¹¹ C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. <i>Nuclear Medicine and Biology</i> , 2016, 43, 52-62.	0.6	3
107	Adenosine _{2A} Receptor Occupancy by Long-term Istradefylline Administration in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 268-269.	3.9	3
108	Pharmacokinetic Modeling of (R)-[¹¹ C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates. <i>Molecular Pharmaceutics</i> , 2021, 18, 416-428.	4.6	3

#	ARTICLE	IF	CITATIONS
109	Determination of radionuclides and radiochemical impurities produced by in-house cyclotron irradiation and subsequent radiosynthesis of PET tracers. <i>Annals of Nuclear Medicine</i> , 2017, 31, 84-92.	2.2	2
110	Correlation of ^4H -[methyl- ^{11}C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas. <i>Annals of Nuclear Medicine</i> , 2018, 32, 634-641.	2.2	2
111	Interim ^4H -[methyl- ^{11}C]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [^{18}F]FDG PET. <i>EJNMMI Research</i> , 2021, 11, 13.	2.5	2
112	Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2615-2623.	6.4	2
113	In Vivo Evaluation of ^{11}C -labeled Three Radioligands for Glycine Transporter 1 in the Mouse Brain. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012, 10, 34-43.	2.0	2
114	Use of ^{11}C -4DST-PET for Imaging of Human Brain Tumors. <i>Tumors of the Central Nervous System</i> , 2014, , 41-48.	0.1	2
115	Synthesis and evaluation of N-isopropyl-p-[^{11}C]methylamphetamine as a novel cerebral blood flow tracer for positron emission tomography. <i>EJNMMI Research</i> , 2020, 10, 115.	2.5	2
116	Texture indices of ^4H -[methyl- ^{11}C]-thiothymidine uptake predict p16 status in patients with newly diagnosed oropharyngeal squamous cell carcinoma: comparison with ^{18}F -FDG uptake. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 20.	1.5	2
117	Roles of $\text{f}1$ receptors in the mechanisms of action of CNS drugs. <i>Translational Neuroscience</i> , 2012, 3, .	1.4	1
118	Optimization of the alkyl side chain length of fluorine-18-labeled ^7H -alkyl-fluoroestradiol. <i>Nuclear Medicine and Biology</i> , 2016, 43, 512-519.	0.6	1
119	Synthesis and basic evaluation of ^7H -(3-[^{18}F]fluoropropyl)-testosterone and ^7H -(3-[^{18}F]fluoropropyl)-dihydrotestosterone. <i>Annals of Nuclear Medicine</i> , 2017, 31, 53-62.	2.2	1
120	Density of metabotropic glutamate receptors subtype 1 in Parkinson's disease compared to healthy elderly - a ITMM PET study -. <i>Journal of the Neurological Sciences</i> , 2017, 381, 806-807.	0.6	1
121	Usefulness of ^{11}C -Methionine Positron Emission Tomography for Monitoring of Treatment Response and Recurrence in a Glioblastoma Patient on Bevacizumab Therapy: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 442-449.	0.7	1
122	Radiosynthesis of ^{18}F -labeled d-allose. <i>Carbohydrate Research</i> , 2019, 486, 107827.	2.3	1
123	Pre-discard estimation of radioactivated materials in positron emission tomography cyclotron systems and concrete walls of a cyclotron vault. <i>Medical Physics</i> , 2019, 46, 2457-2467.	3.0	1
124	Correlation of ^4H -[methyl- ^{11}C]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma. <i>EJNMMI Research</i> , 2021, 11, 42.	2.5	1
125	PET Imaging of Sigma1 Receptors. , 2014, , 741-763.		1
126	Brain Imaging of Sigma Receptors. , 2014, , 99-112.		0

#	ARTICLE	IF	CITATIONS
127	Human Brain Imaging of Acetylcholine Receptors. , 2014, , 113-160.		0
128	PET imaging for altered brain function evoked by exercise: measurements of changes in cerebral blood flow and neurotransmitters. No Junkan Taisha = Cerebral Blood Flow and Metabolism, 2017, 28, 297-302.	0.0	0
129	Validation of scatter limitation correction to eliminate scatter correction error in oxygen-15 gas-inhalation positron emission tomography images. Nuclear Medicine Communications, 2018, 39, 936-944.	1.1	0
130	Correlation of 4â€²-[methyl-11C]-thiothymidine PET with Ki-67 immunohistochemistry separately in patients with newly diagnosed and recurrent gliomas. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 1322-1327.	1.1	0
131	First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the bloodâ€²brain barrier. Annals of Nuclear Medicine, 2021, 35, 1240-1252.	2.2	0
132	Testâ€²retest reproducibility of cerebral adenosine A2A receptor quantification using [11C]preladenant. Annals of Nuclear Medicine, 2022, 36, 15-23.	2.2	0
133	Cerebral Blood Flow during Dynamic Exercise Correlates with Blood Pressure in Autonomic Brain Regions. Medicine and Science in Sports and Exercise, 2017, 49, 824.	0.4	0
134	Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid I ² , an Alzheimerâ€²s disease pathology. Aging, 2020, 12, 19701-19710.	3.1	0